NCI-H322 Cell Line human

NCI-H322 has been used to study the preclinical antitumor efficacy of BAY 1129980, which is an anti-C4.4A (Ly6/PLAUR domain-containing protein 3 precursor-LYPD3) antibody–drug conjugate for the treatment of non–small cell lung cancer.

Test system for evaluating cytotoxicity and genotoxicity of chemicals to human lung

Human Caucasian bronchioalveolar carcinoma

NCI-H322 was derived in 1981 from a primary bronchioalveolar carcinoma of the lung from a 52 year old male taken prior to treatment. Ultrastructural studies of this non-small cell carcinoma cell line demonstrated the presence of cytoplasmic structures characteristic of Clara cells. NCI-H322 do not express UDP-glucuronosyltransferase, but are reported to express glutathione-S-transferase and phenol sulfotransferase. Expression of protein and RNA of SP-A, the major surfactant-associated protein was detected. The cells produce tumours in athymic mice.

RPMI 1640 + 2mM Glutamine + 5-10% Foetal Bovine Serum (FBS).

Split sub-confluent cultures (70-80%) 1:3 to 1:6 i.e. seeding at 1-3x10,000 cells/cm² using 0.25% trypsin or trypsin/EDTA; 5% CO₂; 37°C.

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.

This cell line is part of the European Collection of Authenticated Cell Cultures (ECACC), an international repository managed by the United Kingdom Health Security Agency (UKHSA). No licensing agreement is required when either this cell line or the DNA extracted from it are used for internal research purposes only. Any other use of these products is prohibited without the express written permission of UKHSA. Inquiries regarding authorized use of this cell line or its genomic DNA may be directed to culturecollections@ukhsa.gov.uk.